0001104659-20-137408.txt : 20201218
0001104659-20-137408.hdr.sgml : 20201218
20201218160416
ACCESSION NUMBER: 0001104659-20-137408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201216
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Matushansky Igor
CENTRAL INDEX KEY: 0001768208
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38869
FILM NUMBER: 201400632
MAIL ADDRESS:
STREET 1: C/O HOOKIPA PHARMA INC.
STREET 2: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HOOKIPA Pharma Inc.
CENTRAL INDEX KEY: 0001760542
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 815395687
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
STREET 2: 14TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 0114318906360
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
STREET 2: 14TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
4
1
tm2038926d1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-12-16
0
0001760542
HOOKIPA Pharma Inc.
HOOK
0001768208
Matushansky Igor
C/O HOOKIPA PHARMA INC.
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240
NEW YORK
NY
10118
0
1
0
0
Chief Medical Officer
Common Stock
2020-12-16
4
M
0
640
0.10
A
56774
D
Common Stock
2020-12-16
4
S
0
380
11.70
D
56394
D
Common Stock
2020-12-17
4
M
0
19360
0.10
A
75754
D
Common Stock
2020-12-17
4
S
0
11501
11.70
D
64253
D
Common Stock
2020-12-17
4
M
0
29628
0.10
A
93881
D
Common Stock
2020-12-17
4
S
0
16478
11.76
D
77403
D
Stock Option (Right to Buy)
0.10
2020-12-16
4
M
0
640
0
D
2026-12-31
Common Stock
640
39735
D
Stock Option (Right to Buy)
0.10
2020-12-17
4
M
0
31656
0
D
2026-12-31
Common Stock
31656
8079
D
Stock Option (Right to Buy)
0.10
2020-12-17
4
M
0
11367
0
D
2026-12-31
Common Stock
11367
14208
D
Stock Option (Right to Buy)
0.10
2020-12-17
4
M
0
5965
0
D
2026-12-31
Common Stock
5965
7669
D
The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 121,133 shares.
25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 31,258 shares.
25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 5,965 shares.
/s/ Reinhard Kandera, as Attorney-in-Fact
2020-12-18